Germany's immatics biotechnologies GMBH is establishing a US subsidiary in Houston on the campus of MD Anderson Cancer Center, and the two will work together to produce new cancer immunotherapies derived from immatics' XPRESIDENT technology platform.
Immatics Teams With MD Anderson On Novel Immuno-Oncology Targets
Germany's immatics biotechnologies GMBH is establishing a US subsidiary in Houston on the campus of MD Anderson Cancer Center, and the two will work together to produce new cancer immunotherapies derived from immatics' XPRESIDENT technology platform.